Compassionate use of remdesivir in children with COVID-19
- 1 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 180 (4), 1317-1322
- https://doi.org/10.1007/s00431-020-03876-1
Abstract
Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children. A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months-11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom. Conclusions: In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases.This publication has 11 references indexed in Scilit:
- Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, SpainJAMA Pediatrics, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019JAMA Pediatrics, 2020
- Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2Journal of the Pediatric Infectious Diseases Society, 2020
- COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyThe Lancet Child & Adolescent Health, 2020
- Clinical outcome of SARS-CoV-2 infection in immunosuppressed children in SpainEuropean Journal of Pediatrics, 2020
- Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive studyJournal of Clinical Virology, 2020
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposalThe Journal of Heart and Lung Transplantation, 2020